Compare Danaher Corporation (DHR) vs Fabrinet (FN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Fabrinet — how do they compare? Danaher Corporation trades at $217.43 (market cap $152.87B), while Fabrinet trades at $501.75 (market cap $17.46B). The key difference: Danaher Corporation is far larger — about 8.8× Fabrinet's market cap, and Danaher Corporation pays a 0.74% dividend while Fabrinet pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Fabrinet for 30 Days on average.
| DHR | FN | |
|---|---|---|
Market Cap | $152.87B | $17.46B |
Volume | 5,228,698 | 1,199,886 |
Sector | Health | Technology |
52-Week High | $242.05 | $746.47 |
52-Week Low | $161.91 | $361.94 |
Typical Hold Time | 69 Days | 30 Days |
Enterprise Value | $175.08B | $16.59B |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, up 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $24.57B in 2025, though net margins have compressed from historical highs. A quarterly dividend of $0.40 was declared, payable in October 2026.
The outlook remains positive given earnings momentum and institutional accumulation, but valuation multiples are elevated. Risks include margin pressure and high capital expenditure in 2026. The consensus price target of $230.31 implies modest upside, supported by 70% buy ratings from analysts.
Fabrinet (FN) trades at $497.99, up 1.81% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals, including a 45% year-over-year revenue growth in Q4 2026 and consistent earnings beats, driven by surging AI data center demand. Valuation ratios like P/E of 37.34 and P/S of 3.81 reflect high growth expectations. Recent news highlights capacity expansion and AI-driven growth, though high RSI levels suggest potential overbought conditions.
The outlook for FN is positive, with a consensus price target of $769.50 implying significant upside. Key opportunities include AI infrastructure demand and operational leverage, but risks involve customer concentration, margin pressure from high spending, and insider selling. Investors should weigh strong growth prospects against valuation and execution risks in a competitive sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →
